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Abstract Asthma is an in£ammatory disorder inwhich the small airways of the lung play an important role.There is
also evidence for the systemic nature of asthma. No current method adequately measures small airways function
alone. Therefore, a combination of functional and clinical parameters should be used to ensure that patients with
asthma are adequately treated with due consideration of the small airways. Previously, therapeutic strategies
have focused on bronchodilation and attenuation of airway in£ammation.While early oral therapies had the advantage
of reaching the small airways andtreating the systemic aspectof asthma, theywere associatedwith serious side-e¡ects.
Inhaled therapieswere therefore developed to limitthese e¡ects.However, inhaled therapies have the disadvantage of
limitedpenetration into the peripheral airways and aninability to treatthe systemic componentof asthma.They are also
associatedwithlocal and systemic side-e¡ects.The future for asthmatreatmentislikely tobe a systemicallyadministered
medicationwith fewside-e¡ects targetingdisease-speci¢cmediators.Theleukotrienereceptor antagonists andanti-IgE
monoclonal antibodies are examples of such therapies and the emergence of other new strategies is awaited.
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Asthma is one of themost common respiratory diseases
and its prevalence is increasing in developed countries.
Treatment for asthma has been available for centuries,
with ancient Egyptian, Hebrew and Greek writings all
referring to the condition.The Ebers Papyrus (1550 BC)
refers to the treatmentof a respiratory condition, which
was probably asthma, with herbs, enemas and the ad-
ministration of animal excrement (1).The Chinese were
also familiar with asthma and early writings (1000 BC)
mention inhalations using plants that have in modern
times been found to contain the adrenergic agent ephe-
drine (2).Homer used the term‘asthma’ in the Iliad to de-
note panting or distressed breathing. Hippocrates also
viewed asthma as a similar syndrome (3).
Aretaeus (2nd century AD) of Cappadocia provided
the ¢rst recognizable clinical descriptions of asthma as aCorrespondence should be addressed to: Prof. Leif Bjermer M.D.,
Department of Lung Medicine,University Hospital, 7006 Trondheim,
Norway.Fax: +47 73 867424; E-mail: leif.bjermer@medisin.ntnu.nodisease and not merely a symptom. He described the
symptoms of asthma as ‘. . .a heaviness of the chest, slug-
gishness to one’s accustomed work and to every other
exertion, di⁄culty in breathing on a steep road . . .’ and
‘. . .during the remissions, though they may walk erect,
they hear the traces of the a¡ection’ (4). However, de-
spite this recognition of asthma as a distinct condition,
for many years it was still treated as a symptom rather
than a disease.
Records from the 16th century document the treat-
mentof JohnHamilton, Archbishop of St Andrews, Scot-
land who had severe asthma. His physician
recommended, among other things, avoiding the use of
feathers in his bed (5). In the 17th century, Jean van Hel-
mont, who su¡ered from asthma himself, described
asthma as a ‘drawing together of the bronchi.’ He also
provided the earliest reference to the aetiology of an at-
tack in his description of a monk who ‘as oft as any place
is swept or thewind doth otherwise stir up the dust, he
presently falls down almost choked’ (6).
William Osler (1849^1919) made the ¢rst reference to
in£ammation in the pathogenesis of asthma when he in-
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mucus intohismodelof the asthmatic process (7). In1879,
Ehrlichobservedeosinophils in the sputumofpatientswith
asthma, although from his book it would appear that
Henry Hyde Salter (1823^1871) might have noted the pre-
sence of eosinophils sometimebefore this (7).
In the early 1800s, asthma relief was reportedly
achieved through the smoking of leaves from Datura
plants (8), which are now known to contain anti-choli-
nergic alkaloids. However, despite the wealth of histori-
cal knowledge about asthma and its treatment, and the
gradual realisation that it is a distinct diseasewith a spe-
ci¢c set of causes and clinical consequences, there was
very little understanding of the pathogenesis of asthma
or its treatment until the early1900s.
DEVELOPMENTOF THE
UNDERSTANDINGOFASTHMA
PATHOGENESIS
Asthma as an in£ammatory lung disorder
Asthma was initially regarded as an abnormal contracti-
lity of the smooth muscles in the airways, as illustrated
by the 1962 American Thoracic Society de¢nition (9).
Bronchial asthmawas recognized by
‘recurrent episodes of air£ow limitation that are
usually reversible either spontaneously or with ap-
propriate treatment’ (9).
However, improved understanding of the disease pro-
cess has altered our view of asthma and it is now consid-
ered mainly as an in£ammatory airway disorder,
associated with heightened airway responsiveness to a
variety of bronchial stimuli (10). Post-mortem studies
have subsequently provided supporting evidence for the
concept that airway in£ammation is the key process in
asthma (11^16).
The latest Global Initiative for Asthma (GINA) guide-
lines de¢ne asthma as
‘a chronic in£ammatory disorder of the airways in
which many cells play a role, in particular mast
cells, eosinophils, and T-lymphocytes’ (17).
This in£ammation causes recurrent episodes of wheez-
ing, breathlessness, chest tightness, and cough particu-
larly at night and/or in the early morning. These
symptoms are usually associated with widespread but
variable air£ow limitation that is at least partly reversi-
ble either spontaneously or with treatment.The in£am-
mation also causes airway hyper-responsiveness to a
variety of stimuli (17).
An active in£ammatoryprocess is present, even in the
asymptomatic patient. Chronic in£ammatory reactionsare central to the disease process and underlie the func-
tional airway abnormalities and air£ow limitation in asth-
ma. Chronically in£amed airways are associated with
remodelling, and airways become hyper-responsive and
obstructed as air£ow is limited by smooth muscle con-
traction, ¢brosis, oedema, excessmucus production and
in¢ltrating in£ammatory cells. Thus, uncontrolled in-
£ammation in asthma leads to bronchoconstriction and
hyper-responsiveness.
The recognition of asthma as an in£ammatory disor-
der was a major breakthrough in the history of treating
this disease, shifting the focus of treatment frombronch-
odilating to anti-in£ammatory drugs. The goal of any
asthma treatment should be to suppress airway in£am-
mation and modify progression of the disease as this
strategyhaspotential long-term implications for improv-
ing themorbidity of asthma.
Asthma as a systemic disorder
Evidence suggests that di¡erent regions of the airways
are pathophysiologically linked (18), with in£ammation
arising in regions from thenose to the alveoli. In addition,
the presence of in£ammatory mediators in the circula-
tion provides support for the systemic nature of asthma.
Asthma and rhinitis
Asthma and allergic rhinitis often co-exist (19^21). Ap-
proximately 20%of childrenwith allergic rhinitis laterde-
velop asthma or wheezing (22) and the converse also
applies.For example, 50% of patients with asthma devel-
op allergic rhinitis (23).
The pathophysiological link between the upper and
lower airways is supported by several observations.
First, the prevalence of bronchial hyper-responsiveness
is higher in patients with allergic rhinitis compared with
normal subjects despite a lackof clinical evidence of asth-
ma (24^27). Second, patients with perennial rhinitis
show increased levels of bronchial hyper-responsiveness
compared to those with seasonal rhinitis (28,29). Finally,
bronchial hyper-reactivity in patients with seasonal rhi-
nitis increases during the allergen season and decreases
during the‘o¡-season’ (30^32).
There is also support for a linkbetween theupper and
lower airways in non-atopic asthma. Eosinophils have
been identi¢ed in the nasalmucosa of asthmatic patients
even in the absence of rhinitis, and these ¢ndings provide
further evidence for asthma and rhinitis being clinical ex-
pressions of the same disease process (33).
These ¢ndings are substantiated by studies examining
levels of exhaled nitric oxide. In patients with asthma, al-
lergen-induced in£ammation is associated with elevated
exhaled nitric oxide concentrations (34). This has led to
theproposal of exhalednitric oxide as an indirectmarker
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centration of exhaled nitric oxide is increased in hyper-
responsive subjects, and decreases signi¢cantly after
methacholine-induced bronchoconstriction, suggesting
that nitric oxide production occurs in the peripheral air-
ways (32). Patients with allergic rhinitis also have in-
creased levels of exhaled nitric oxide indicating an
ongoing in£ammatory activity in the lower airways
(32,36).
Themarkedin¢ltration of eosinophils into a¡ected tis-
sues during allergic in£ammation is a clinical feature asso-
ciated with asthma, allergic rhinitis and atopic
dermatitis. However, there is now also considerable evi-
dence that the bone marrow plays an integral role in al-
lergic in£ammation (37).
Asthma and bone marrowconnection
In asthma, allergen exposure in the airway activates a
systemic response that provokes in£ammatory cell pro-
ductionby thebonemarrow (38).Bonemarrowprogeni-
tor cells proliferate and di¡erentiate, leading to a
persistent increase in the numbers of mature basophils,
eosinophils andmast cells in both the circulation and air-
way tissues (39^42).These observations provide further
support for theproposition that asthma is a systemicdis-
ease (37).Basophils and eosinophils play a signi¢cantrole
in promoting allergic in£ammation (43^45), and in aller-
gic subjects these cells are increased and activated com-
paredwith non-atopic control subjects.
T-cell recruitment to the lungs is thought to play a key
role in airway in£ammation.Current understanding sug-
gests that the local airway eosinophilia and IgE-depen-
dent mast cell activation characteristic of asthmatic
in£ammation are regulated by cytokines derived from
type 2 T-helper lymphocytes (Th2 T cells).T2 cells co-or-
dinate and amplify the e¡ector functions of antigen-spe-
ci¢c and non-speci¢c proin£ammatory cells such as B
cells and eosinophils.TheTh2 cells in particular promote
allergic in£ammation though proin£ammatory cyto-
kines. The parallel changes inT-cell activation and cyto-
kine production are detectable in peripheral blood as
well as in the bronchial mucosa and re£ect the systemic
nature of asthma (46).
Asthma and atopicdermatitis
Like asthma and rhinitis, atopic dermatitis is also asso-
ciated with elevated IgE, circulating T cell levels and eo-
sinophilia (47). Additionally, 80% of children with atopic
dermatitis will ultimately develop asthma or allergic rhi-
nitis (48). A number of observations suggest that the
course of asthma is a¡ected by atopic dermatitis
(47,49,50), further supporting the presence of a systemic
response.Thus, asthma shouldbe regarded as a systemic disease
sharing features with other compartments of the body
as the nose, skin and bone marrow. It is di⁄cult to
achieve optimal asthma control in a patient with asthma
and rhinitis without also treating the nose. The same
probably applies for concomitantmanifestations in other
parts of the body.This view of asthma as a potential sys-
temic disorder supports the use of systemic therapeutic
modalities (46).
ASTHMAASADISEASEOF THE
SMALLAIRWAYS
The small airways of the lung are those bronchial pas-
sages 52mm in diameter located beyond the seventh
or eighth generation of the bronchial tree and these air-
ways account for approximately 80% of the lung total
surface area (51). Asthmatic in£ammation is now known
to be present in the smaller airways in addition to the
large central and intermediate-sized airways (18,52).
Evaluation of the small airways
In normal subjects, the small airways provide only10% of
the total airway resistance (53^55). This has led to the
small airways being termed the ‘silent zone’ since air£ow
obstruction within them causes little change in the con-
ventional tests of pulmonary function (10,53,56). How-
ever, the di⁄culties involved in performing physiological
measurements speci¢c for this site and in vivo sampling
has led to the considerable under-evaluation of the small
airways (57,58). Although an early study (59) suggested
that the small airways are clinically ‘silent’ in asthma, la-
ter studies found that this is not the case (60). A study
using speci¢c airway conductance techniques (pressure-
£ow data) instead of spirometric measurements, found
that even in mild asthma therewas a seven-fold increase
in peripheral airwayresistance compared to healthy sub-
jects despite the fact that pulmonary function did not
di¡er between the two groups (60).
Functionalmeasurements
Although small airway disease is a key feature of asthma,
studies comparing central and peripheral airways sug-
gest that the simplemeasurements of lung function used
clinically focusmore on events in the large airways.Thus,
improvements in theseparametersmay notre£ect small
airway pathology (10).
Lung function
Theparameters used to assess the severity of asthma in-
clude forced expiratory volume in 1sec (FEV1), which
mainly measures large airway function (61), and peak
706 RESPIRATORYMEDICINEexpiratory £ow (PEF). However, clinical data suggest
thesemeasurements do not always correlatewith other
markers of disease activity (62). For example, while sub-
stantial improvementsmayoccur in a numberof clinically
relevant non-physiological measures such as daytime
symptom scores, nocturnal awakenings due to asthma,
use of b2-agonist rescue medication, quality of life and
frequency of acute asthma exacerbations, only relatively
modest changes in FEV1may be seen (Fig.1) (63,64).This
maybe due to a physiological improvement in air£ow ob-
struction in the small airways that is not re£ected in the
FEV1response (65,66).The correlation between PEF and
symptoms of asthma is also poor (63).
The presence of an enhanced in£ammatory process in
the small airways is consistentwith an increase in periph-
eral airwayresistance (67).Directmeasurementof intra-
bronchial pressure with a catheter-tipped microman-
ometer showed that while central airway resistance
showed a tendency to increase in patientswith bronchial
asthma, only peripheral airway resistance increased sig-
ni¢cantly (67).These observations, together with the ‘in-
sensitivity’ of FEV1 in re£ecting asthma outcomes,
suggest the peripheral airways are an important site of
air£ow obstruction, irrespective of the di¡erent patho-
genesis of chronic air£ow obstruction.
Flow volume spirometry
In asthma patients with near normal FEV1and forced vi-
tal capacity (FVC) values, the change in £owrates atmid
to low lung volume (FEF25^75%) has been shown to be sig-
ni¢cantly lower in patients with asthma (77?4% pre-
dicted) when compared with normal subjects (93?5%
predicted, P=0?047) (60). This suggests that FEF25^75%
may be a more sensitive measure of the calibre andFIG. 1. Relationship between FEV1 and symptom scores.
Adapted fromTeeter and Bleecker,1998 (63).function of the small airways (68).Therefore, in these pa-
tients, outcomes may be better monitored using spiro-
metric methods that pay more attention to changes in
FEF25^75% as an indicator of small airway function than
more conventionalmethods (69).
In patients with more advanced disease with episodic
or more persistent bronchial obstruction, FEF25^75% is a
less valuable measure of small airway involvement. In
these patients, £ow limitation in the lower airways is ac-
companied by areas in which complete obstruction oc-
curs resulting in air-trapping, decreased FVC and
increasedresidual volume (RV). Since FEF25^75% is related
to FVC, a substantial decrease in FVC may give a
falsely high FEF25^75% (Fig. 2). Thus, when £ow-volumeFIG. 2. Flow volume spirometery and the small airways. (a)
FEF25^75% represents mean £ow between 25% and 75% of
FVC; (b) when air trapping occurs FVC decreases (volume re-
sponse), thus FEF25^75% does not appropriately re£ect the ob-
struction occurring; (c) FEF25^75% is related to baseline FVC
beforeprovocation; inthis situationincreasingobstructionis also
re£ectedby FEF25^75% when FVCdecreases after provocation.
FIG. 3. Example of air trapping in a patient with asthma.
Adapted from Laurent et al.,1998 (83).
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ment, both FVC and FEF25^75% should be considered.
In conclusion, FEF25^75% may indicate small airways
function in some instances, such as very mild asthma
without variable FVC.However, in general, it is not a de-
¢nitivemeasure of small airways involvement.
A number of physiological parameters that are more
sensitive than FEV1 for small airways disease have been
identi¢ed (70), including measures derived from single-
breath nitrogen wash-out and volume of iso£ow com-
paring air and helium on the £ow-volume curve. How-
ever, while sensitive, these are not speci¢c for small
airway disease and may also be a¡ected by changes in
large airway function.Closing volume is a more speci¢c
indicator of small airway function, but shows a high de-
gree of inter-subject variability (71,72). Density depen-
dence of £ow measurements are sensitive indicators of
peripheral airways function (73) but their utility is lim-
ited by a high degree of test^retest variability (74).
Computed tomography
High-resolution computed tomography (HRCT) scan-
ning captures ¢ne lung detail and can demonstrate mor-
phological changes in the small airways associated with
dysfunction that are too subtle to be identi¢ed through
conventional lung functionmeasurements alone (75^79).
Advances in HRCTscanning have alsomade it possible to
obtain non-invasive, reproducible measurements of
structure^ function relationships within the small air-
ways and an in vivo assessment of drug deposition
(76,77,80).
HRCT techniques allow measurement of the changes
in regional air-trapping that accompany changes in small
airways calibre (76,81).TheHRCTappearance of small air-
ways during a suspended breath-hold at residual volume
(RV) comprises patchy areas of high and low attenuation
of the lungparenchyma; known as ‘mosaic perfusion’.This
is thought to be a consequence of re£ex vasoconstric-
tion in under-ventilated areas of the lung (82). Patients
su¡ering frommoderate asthma present larger areas of
air-trapping and mosaic perfusion than normal subjects,
particularly in non-dependent areas of the lung (Fig. 3)
(83). Air-trapping may take the form of complete ob-
struction (assessed using HRCT or increases in RV) or
narrowingwhichresults in reducedair£owin theperiph-
eral airways (measured by FEF25^75%). A signi¢cant posi-
tive correlation exists between the amount of air-
trapping and the extent of small airways alteration (83).
Air-trapping can be quanti¢ed by analysis of lung at-
tenuation curves (LAC) at RV. A shift to the left in the
LAC (i.e. to lower attenuation) represents an increase
in air-trapping. Such shifts are demonstrated in patients
with mild asthma after methacholine inhalation, even in
the absence of any detectable change in FEV1, indicating
hyper-reactivityof theperipheral airways (76,84). A shiftto the right of the LAC (i.e. to higher attenuation), re-
£ects reduced air-trapping and corresponds to an im-
provement in small airways calibre.
Air-trapping scores show a greater correlation with
HRCT scans than with lung function tests such as FEV1,
FRC and RV (83). This suggests that HRCT scans may
yield information not provided by lung function tests
(83) and provides further evidence that obstruction in
the small airways does not a¡ect FEV1.
Scintigraphy
Isotope inhalation studies provide a functionalmethod of
evaluating aerosol deposition in the lower airways.Data
from such studies have shown that methacholine-in-
duced bronchoconstriction a¡ects drug deposition by
preventing inhaled medications from reaching the lung
periphery (Fig. 4) (85).Consequently, the majority of in-
haled drug is deposited in themore central airways (86).
Thismayexplainwhypatientswith asthma show less sys-
temic availability of inhaled corticosteroids compared
with normal subjects, simply because the drug does not
penetrate deep enough into the lung to be systemically
absorbed.
FIG. 4. Ventilation scintigraphy on a patient with baseline nor-
mal lung function, before and after metacholine provoked
bronchoconstriction.Bronchoconstriction leads to an increased
amount of drug being deposited in the central compared to the
peripheral parts of the airways. Adapted from Laube et al.,1986
(85).
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Techniques such as transbronchial biopsy, bronchoalveo-
lar lavage, post-mortem tissue analysis and levels of ex-
haled nitric oxide have all indicated that extensive
mucosal in£ammation occurs in the small airways. Re-
cent studies con¢rm these morphological ¢ndings and
demonstrate the presence of signi¢cant small airway in-
£ammation in asthma (18,87,88). Asthma is associated
with an increase inT cells and total and activated eosino-
phils in all airways, comparedwithpatientswithout asth-
ma (P50?001) (18). However, in asthma, the number of
activated eosinophils present in the small airways is sig-
ni¢cantlygreater than in the large airways (P50?05) (18).
These results are indicative of the presence of a more
severe in£ammatory process in the peripheral airways
than in the large central airways,which is consistentwith
the smaller airways being a major site of pathology in
asthma (18,89).The presence of greater numbers of eosi-
nophils in small airways comparedwith the large airways
and parenchyma has also been con¢rmed by histochem-
ical staining (18,90).These ¢ndings are further supported
by a computational analysis based on quantitative histol-
ogy, which showed that the peripheral airways account
for the majority of the airway hyper-responsiveness in
asthma (91,92).
There are also di¡erences between the airways re-
garding the location of eosinophils within them. The
small airways have a preponderance of eosinophils in
their ‘outer’ region (between smooth muscle and alveo-
lar attachments), while in large asthmatic airways the
greatest density of eosinophils lies in the ‘inner’ region
(between basement membrane and smooth muscle)
(93).The increased T cell accumulation and eosinophil ac-
tivation seen in the small airways suggest that in£amma-
tion at this site is a key feature of the pathogenesis of
asthma. This di¡erence in the location of eosinophils in
the large and small airways may have implications when
anti-in£ammatory treatment is given via the inhaled
route. E¡ective treatment of in£ammation situated dee-per in the tissue should theoretically require a higher
dose of inhaledmedication in order for the drug topene-
trate into the tissue and penetration may not be com-
plete. However, in reality the concentration of inhaled
drugs is lower in the peripheral airways than in the cen-
tral airways (94). A study of the distribution of inhaled
£uticasone propionate showed that the concentration
achieved in the peripheral airways was three to four
times lower than that in the central airways (94).
Clinical correlates of small airway function
Exacerbations in asthma. Di¡erences in the degree of
small airway involvement re£ected by di¡erences in
closing volume appear to distinguish between those pa-
tients with and without frequent acute exacerbations of
asthma, despite similar FEV1 values (95). In£ammatory
obstruction in small airways may predispose patients to
excessive airway closure and to frequent exacerbations.
Nocturnal asthma. Studies in nocturnal asthma have
shown that the in£ammatory response in the airways is
considerably greater at night (88,96^98). The acute al-
teration in symptoms at night is associated with cellular
in¢ltration and increased numbers of eosinophils and
CD4 lymphocytes preferentially in the peripheral air-
ways and alveoli rather than the proximal airways
(Fig. 5) (98,99).This suggests in£ammation in the periph-
eral airways and alveolimay be responsible for the acute
worsening of the condition. The persistence of alveolar
in£ammation in patients with nocturnal asthmawho are
treated with inhaled steroids suggests that inhaled anti-
in£ammatorymedicationsmaynot target this important
area of involvement in asthma (97).
Exercise-induced asthma. Exercise-induced asthma (or
exercise-inducedbronchospasm) is a common condition,
occurring in up to 90% of previously untreated patients
with asthma (100). Current evidence suggests that the
stimulus of airway cooling and/or drying is translated
into air£ow limitation as a result of the narrowing of
the airways (101).For example, patients with exercise-in-
duced asthma demonstrate an increase in peripheral re-
sistance following challenge with cool, dry air which
correlates with airway hyper-responsiveness (102). Sub-
sequent studies have shown that the peripheral resis-
tance in patients with mild asthma and exercise-induced
asthma is greater than that of normal subjects. This
further suggests that fewer peripheral airways are avail-
able for ventilation in these patients (103).
Decline in lung function. Chronic poorly controlled in-
£ammation in the peripheral airways may contribute to
FIG. 5 The median number per volume of eosinophils in patients with nocturnal (&) and non-nocturnal asthma (&) at (a) 16.00
hours and (b) 04.00 hours.Adapted fromKraft et al.,1996 (98).
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age (104,105) and notably in patients with newly diag-
nosed asthma (106). A recent study has shown that
neither nedocromil nor inhaled corticosteroids a¡ect
the disease progression of asthma in terms of improved
lung function asmeasured by FEV1 (107).Whether this is
due to a lack of in£ammatory control as a result of insuf-
¢cient deposition in the peripheral airways or because
steroids do not a¡ect all parts of the in£ammation is an
open question. Similar data from long-term studies
which evaluate the newer anti-in£ammatory drugs, such
as the leukotriene receptor antagonists, are required.
In addition to in£ammation, airway remodelling (in-
creased wall thickness, smooth muscle area and in£am-
matory cell in£ammation) also occurs throughout the
peripheral airways (16,19,88,108). A 15-year follow-up of
theCopenhagenHeart Studyhighlighted the ongoing tis-
sue injury and repair associated with asthma that may
reduce the distensibility of the lungs (109) and adversely
a¡ect lung function as assessed by FEV1 (104).
The structural airway changes resulting from in£am-
mation may have more profound physiological conse-
quences within the small distal airways than in the large
proximal airways (91). Studies showevidence of increases
in the thickness of the inner airway walls and in£amma-
tion of small airways in mild to moderate disease.These
changes are most striking in cases that progress to
chronic asthma and to fatal attacks (108). Therefore, it
may be more important than previously appreciated to
identify and treat in£ammation at this level early in the
disease process to prevent airway remodelling and pro-
gression to airway ¢brosis and irreversible damage (110).
In£ammation of the small airways may also cause them
to act as a reservoir of in£ammatory mediators, which
then rise up the bronchi and provoke symptoms in the
larger airways (19).Small airways summary
Due to the challenges in evaluating the small airways, this
part of the lunghas not been studied to the same level of
detail as the larger airways. Standard tests of lung func-
tion are probably a poor guide to small airway disease,
causing the condition to be easily overlooked.Large per-
centage changes in peripheral resistance have a relatively
small impact on airways resistance and thus, by implica-
tion on FEV1 and PEF measurements. Both parameters
are therefore unreliable re£ections of events in the small
airways (10).
No single method currently available is su⁄ciently
adequate to solely measure small airways function.
Therefore, an evaluation should be based on a combina-
tion of functional and clinical parameters and each pa-
tient should be treated with consideration of small
airways function.
The increased T cell accumulation and eosinophil
activation in the small airways show that a severe
in£ammatory process is present in the peripheral air-
ways not routinely biopsied during ¢breoptic broncho-
scopy (18). Moreover, the low resistance of the small
airways means that severe damage and obstruction can
occur in these airways before symptoms occur (82).
Thus, in£ammation at this site is a key feature of the
pathogenesis of asthma.
Because the small airways are intrinsically involved in
the pathogenesis of asthma, further studies are needed
to evaluate this area of the lung, particularly because of
the clinical implications (111,112). Therefore, treatment in
asthma needs to be directed to both the large and small
airways to achievemaximal suppression of in£ammation
throughout the airways (88). Additionally, in the initial
stages of asthma treatment should particularly target
the small airways.
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PHARMACOTHERAPYFORASTHMA
The characterization of chronic asthma as an in£amma-
tory condition associated with heightened airway re-
sponsiveness to a variety of bronchial stimuli, has led to
the development of therapeutic strategies.These strate-
gies have focused on bronchodilation and attenuation of
airway in£ammation.
Early oral therapies for asthma
The initial approach to treating asthma was via the sys-
temic route.The advantages of this were ease of admin-
istration, reliability of drug absorption in reaching the
small airways, penetration of all airways for e¡ective
asthma control and treatment of a systemic disease.The
disadvantages to these early oral therapies were their
serious side e¡ect pro¢les and non-speci¢c targeting of
in£ammatorymediators.
Oral b-agonists
Adrenal extractswere ¢rstused to treat asthma in1900,
when extracts of bovine adrenal gland were found to
have bene¢ts (113). Since then there has been an interest
in the therapeutic use of the hormones produced by the
adrenal gland, namely cortisol and epinephrine (114). By
the 1920s, epinephrine had become the cornerstone
therapy for themanagement of acute asthma (115). How-
ever, when b-agonists are taken orally, muscle tremor,
palpitations, tachycardia and restlessness are common;
and are particularly problematic in the elderly (116).
These adverse e¡ects and a slow onset of action limit
their use in the treatment of asthma.
Oral corticosteroids
In 1936, Compound E was extracted from the adrenal
cortex. It was renamed cortisone in 1939 and by 1950 it
had been successfully used to treat asthma (117).The in-
troduction of oral corticosteroids represented a major
advance in the treatment of asthma due to their anti-in-
£ammatory and immunosuppressive properties.
However, although oral corticosteroids proved to
bevaluable agents for the treatmentof asthma theywere
associated with a plethora of serious side-e¡ects. The
side-e¡ects seen with prolonged usage include peptic
ulcers, osteoporosis and associated fractures,
glaucoma, hyperglycemia, skin thinning and bruising,
mental disturbances (paranoia or depression with risk of
suicide), muscle wasting, Cushing’s syndrome, growth
suppression in children, adrenal atrophy, hypertension
andwater retention.
Short courses of oral corticosteroids are still used to
treat acute attacks of asthma since they are themostpo-tent anti-asthmatic medications known. A high dose
(e.g. prednisolone 30^40mgday71) is administereddaily
for 5^7 days and then discontinued. In chronic asthma,
where the patient has responded poorly to other anti-
asthma agents, continued administration of oral
corticosteroids may be necessary, although high
doses of inhaled steroids are continued to keep the
oral dose to a minimum.Thus, while oral corticosteroids
have the advantage of being able to reach the small
airways, chronic use may result in unacceptable side-
e¡ects (118).
Theophylline
Theophylline was originally isolated from cocoa for use
in asthma therapy. Its tendency to be insoluble and
emetic led to the developmentof a derivative aminophyl-
line, which was more soluble. Theophylline was ¢rst
used in asthma in the 1920s and aminophylline in the
1940s (2).
Theophylline is a relatively weak relaxant of airway
smooth muscle. The positive e¡ects of the drug have
been attributed to a number of small bene¢cial e¡ects
that together may result in a favourable response.These
e¡ects are the strengtheningof diaphragmatical contrac-
tility (119) increasedmucociliary clearance (120) and cen-
tral stimulation of the respiratory drive (121). An
important advantage of theophylline is that it can be ta-
ken orally as a once- or twice-daily slowrelease prepara-
tion. Theophylline is particularly useful for treating
patients who havemore severe asthma and is also bene-
¢cial in nocturnal asthma (122^124).
Theuse of theophyllinehasbecomerestrictedinmod-
ern asthmamanagementmainly due to the narrow ther-
apeutic window and potential dangerous side-e¡ects
upon overdosing.Overdosing is associated with nausea,
headaches and, less frequently, cardiac arrhythmia and
seizures. Therefore, while theophylline is inexpensive,
the need for plasma-levelmonitoring canbe both expen-
sive and inconvenient.
Inhaled therapies for asthma
The high incidence of severe side-e¡ects associatedwith
early oral therapies led to the development of inhaled
therapies in an attempt to limit toxicity. However, the
treatmentgoalwas still the same: long-term suppression
of airway in£ammation plus relief of symptoms with
quick acting bronchodilators (primarily aerosolized b2-
agonists). Current asthma therapy is predominately
delivered by aerosol therapy, and inhalation devices have
been improved over the years. In recent decades,
attempts have been made to re¢ne rather than change
asthma therapy.
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In the early1960smetereddose inhalerswere introduced
for usewith adrenergic agents and isoproterenol inhalers
became widely used in the management of asthma (115).
However, this was followedby a rise in asthmamortality
whichwas linkedby circumstantial evidence to theuse of
high-dose isoproterenol inhalers (125). In1967b-adrenor-
eceptors were found to be separable into two types; b1
(cardiac and gastrointestinal tract) and b2 (lung and
uterus). Increasingly inhaledb2-agonistsbecameavailable
for the treatment of asthma.
The smoothmuscle cells of the airways are presumed
to be the target for b2-agonists.These agents are by far
the most useful bronchodilators used for treating acute,
severe asthma and aremost e¡ectivewhen inhaled (126).
However, b2-agonists lack an anti-in£ammatory e¡ect
and so do not relieve the airway in£ammation central to
the pathogenesis of asthma.
Inhaled short-acting b2-agonists such as albuterol and
terbutaline provide rapid symptomatic relief.When used
at the recommended dosages, these agents have few
side-e¡ects. However, concern exists about the use of
excessive doses (127) sincehigh doses are associatedwith
an increased risk of death and morbidity from asthma
(128^130). It has been subsequently recommended that
inhaled b2-agonists should only be used when needed
and that the goals of treatment are to reduce the need
to a minimum (131).
In addition, tolerance may develop to the anti-asth-
matic e¡ects ofb2-agonists (132,133), although there is lit-
tle evidence for loss of their bronchodilator e¡ects.With
the introduction of long-acting b2-agonists such as sal-
meterol and formoterol, this treatment approach is
being increasingly used in the long-termmanagement of
chronic asthma.The addition of a long acting b2-agonist
to inhaled corticosteroids has proven bene¢cial in im-
proving asthma control, including reducing nocturnal
asthma and the frequency of exacerbations, in adults
with chronic asthma (134).However, it has been di⁄cult
to document the same bene¢cial e¡ect in children
(135,136). As with the short-acting b2-agonists, regular
use of long-acting b2-agonists has been associated with
the development of tolerance and loss of protection
after a short period of regular use. Tolerance is most
commonly seen with triggers that operate via mast-cell
activation, such as adenosine, allergens and exercise.
However, studies have shown a reduced rather than loss
of protection (137^139).
Anti-cholinergic bronchodilators
Anti-cholinergic bronchodilators are less e¡ective than
b 2-agonists in asthma because they only block choliner-
gic bronchoconstriction and have a slower onset of ac-
tion.Cromones
Inhaled cromones control the symptoms of asthma and
e¡ectively block bronchospasm induced by allergens, ex-
ercise, adenosine and sulphur dioxide.Cromolyn sodium
and nedocromil sodium are well tolerated and have no
signi¢cant side-e¡ects (140).Due to their short-lived ac-
tion, cromones must be inhaled two to four times daily
and are considered inconvenient regimens for asthma
(116). They appear to be most e¡ective in patients with
mild asthma, but are not e¡ective for all patients.
Inhaled corticosteroids
The use of cortisone as an inhaled aerosol was ¢rst re-
ported in1951 (141) and in1954 prednisone and hydrocor-
tisone became standard treatments for asthma.
Beclomethasone was introduced in 1969 for topical
use in skin diseases, butwas later adapted for aerosol ad-
ministration (1972) and assumed an importantrole in the
treatment of asthma (2,115).
Inhaled corticosteroids reduce in£ammation and im-
prove pulmonary function, leading to reductions in
symptoms and exacerbations with an acceptable side-ef-
fect pro¢le at the doses usually administered (142).
The introduction of guidelines for asthma therapy has
led to earlier use of inhaled corticosteroids by adults and
children, and increasing prescription for the long-term
prophylactic treatment of asthma.With this increase in
usage has come a growing concern about the safety, par-
ticularly the local and systemic side-e¡ects, of inhaled
corticosteroids. Local side-e¡ects are caused by deposi-
tion of corticosteroids in the upper airway.These e¡ects
may be reducedby the use of a large-volume spacer that
removes most of the fraction of drug that would other-
wise be deposited in the oropharynx (143,144). Rinsing
the mouth may reduce the local deposition associated
with drypowder inhalers.Dysphonia, themost common
local side e¡ect of inhaled corticosteroids, can occur in
more than 50% of patients receiving high-dose therapy
(145).
Systemic side-e¡ects result from gastrointestinal ab-
sorption of the swallowed fraction of the drug as well as
through absorption from the lung (146,147).The use of a
corticosteroid such as budesonide or £uticasone propio-
nate thatundergoes extensive ¢rst-pass hepaticmetabo-
lism canhelp to reduce side-e¡ects fromgastrointestinal
absorption, as less drug enters the systemic circulation
(116).With the use of such drugs, the fraction absorbed
from the lung becomes themajor, unavoidable source of
systemic availability.While it is recognized that systemic
absorption occurs following inhaled administration of
corticosteroids, the dose at which clinically relevant
side-e¡ects occur is controversial. The controversy
stems from the fact that the degree of systemic absorp-
tion depends not only upon theprescribed dose, but also
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ityof theunderlyingdisease.However, somepatientswill
still require oral corticosteroid treatment for optimal
control of their disease, and these drugs have a far great-
er risk of adverse e¡ects.
An additional concern is that compliance with inhaled
corticosteroids is poor (148). One strategy to improve
compliance and clinical control was the introduction of
¢xed combinations of a steroid and a long-acting b2-ago-
nist (salmeterol/£uticasone and formoterol/budesonide).
Combinations with long-acting b2-agonists that have a
fast onset of action and therefore symptom relief feed-
back, may be helpful in improving compliance. However,
the ¢xed combinationsmay provide less £exibility with a
potential riskof over- or under-treatmentresulting from
themasking e¡ect that long-acting b2-agonistsmay have
on in£ammation during worsening of the disease (149).
Therapeutic ratio of inhaled corticosteroids
The safety/e⁄cacy ratio, or therapeutic ratio, of an anti-
asthmatic agent is determined by the relationship be-
tween its dose^responserelationship for clinical e⁄cacy
and its systemic adverse events (150). E⁄cacy can be
measured through the use of recognised clinical end-
points such as FEV1, FEF25^75% and morning PEF. How-
ever, safety must be measured through pharmacological
and pharmacokinetic parameters, combined with clini-
cally relevant endpoints such as adverse events and bio-
chemical and laboratory markers. While an
understanding of the safety/e⁄cacy ratio is important,
it is of more value to understand the therapeutic index
relative to other available anti-asthmatic agents.
Theuse of a relatively lowdose of inhaledbeclometha-
sone dipropionate (BDP, 336mgday71) for 4 weeks in 24
patients with mild and moderate asthma improved pul-
monary function and decreased the frequency of salbu-
tamol use signi¢cantly more than inhaled placebo (151).
However, these improvements were short-lived when
BDP treatment was stopped. Spirometric indices of air-
£ow obstruction decreased to baseline levels 1 week
after BDP treatment was discontinued, although treat-
ment-associated improvements in morning peak £ow
and salbutamol use lasted longer (151). This short ‘o¡-
treatment’e¡ect has also been reported in other studies
(64,152^156).
Despite the clear improvements in pulmonary func-
tion and rescue salbutamol use seen in this study, BDP
treatment caused only a modest and statistically insignif-
icant decrease in the percentage of eosinophils in in-
duced sputum (151). These data suggest that although
asthma symptoms are controlled by relatively low-dose
inhaled BDP treatment, airway in£ammation is not.
Studies showing inhaled corticosteroid treatment
reduces airway in£ammation have used doses of
500^1000mgday71 (157^160). Such studies may not takeinto account the dissociation between the dose needed
to decrease airway in£ammation and that needed to im-
prove clinical indices of asthma control, reduce asthma
symptoms and improve airway calibre (149). It is possible
that the dose^response curve for the e¡ect of a drug on
symptoms may be di¡erent from that of its e¡ects on
bronchial hyper-responsiveness or on eosinophilic in-
£ammation of the airways.
Reduction in airway calibre a¡ects the bioavailability
of inhaled drugs and reduces peripheral drug delivery
(68,161,162). Either increasing the dose or improving drug
delivery could theoretically overcome the reduced bioa-
vailability of inhaledmedication.
The impact ofair-trapping on the use of inhaled
corticosteroids
The presence of air-trapping in asthma limits the poten-
tial for inhaled therapies to reach the site of in£amma-
tion, and in particular, the small airways.
Radiographic techniques have been used in patients
with mild to moderate asthma to compare the e⁄cacy
of an extra-¢ne hydro£uoroalkane (HFA)-propelled cor-
ticosteroid aerosol (HFA-BDP) that is well deposited in
the lung periphery, with a conventional chloro£uorocar-
bon (CFC)-propelled aerosol that does not penetrate
the smaller airways (CFC-BDP) (84). After 4 weeks of
treatment the HFA-BDP aerosol resulted in signi¢cantly
more improvement in air-trapping overall compared
with CFC-BDP. No signi¢cant di¡erence was observed
between the groups with respect to symptoms or spiro-
metricmeasurements.These ¢ndings suggest thatnewer
agents targeting the small airways may improve airway
function. These changes may be clinically relevant in
terms of associated improvement in subjectivemeasure-
ments that are not paralleled by detectable improve-
ment in conventional physiological measures such as
FEV1.Consequently, the deeper penetration of thenewer
inhaled therapies into the lung necessitates the develop-
ment of techniques that enable the e¡ect in the smaller
airways to bemonitored.
The e¡ect of inhaled corticosteroids on the small airways
The presence of in£ammation in the small airways in
asthma has therapeutic implications, as it is not clear
whether inhaled corticosteroids e¡ectively treat this
compartmentof the lung. Inhaled corticosteroid therapy
has been shown to decrease in£ammation in the proxi-
mal airways (163,164) but may not be as e⁄cient in the
smaller airways (18,160,165). Despite the use of inhaled
corticosteroids, patients with chronic asthma may exhi-
bit signi¢cant small airway in£ammation (165) andpersis-
tence of their asthmatic symptoms (166); of those
patients complying with regular prophylactic therapy,
56% still reported asthma symptoms (167). The persis-
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tients with asthma treated with inhaled corticosteroids
could result in ¢brotic changes and ¢xed airway obstruc-
tion in the peripheral lung in the later stages of this dis-
ease (97,99,168).
From the evidence that in£ammatory and structural
changes occur throughout the airways, it is clear that
anti-in£ammatory treatment should be directed at both
the large and small airways to achieve suppression of in-
£ammation throughout the entire bronchial tree. How-
ever, not all metered-dose inhalers and dry powder
inhalers are e⁄cient at speci¢cally depositing medica-
tion in theperipheral airways of the lung (99,169,170).Ven-
tilation scans indicate that in asthma, much greater
aerosol deposition occurs in central airways relative to
peripheral airways (10). Even with optimal inhalation
techniques only 10% of the corticosteroid dose gener-
ated by CFC-based inhalers reaches the lower respira-
tory tract with most medication deposited in the
oropharynx (52,171,172).
Onemethod that has been employed to overcome the
problem of drug delivery to the airways is to alter the
propellant used and hence particle size. Analysis of the
site of deposition of particleswithin the airway in asthma
suggests that particles of the 3^5mm range target the
large, central airways and that particles in the range of
1?5^3mm are needed to reach the peripheral airways
(170).However, 70% of the particles emitted from a stan-
dard CFC-metered dose inhaler are larger than 5mm
(52).The use of a HFA formulation of corticosteroids re-
sults in a propellant that in some cases delivers an aero-
solwith a smallermean particle size than that generated
by conventional CFC-based metered dose inhalers (80).
Theparticle size ofHFA-BDP is1?1mm, three times smal-
ler than that with the conventional CFC-BDP propel-
lant.This formulation has been shown to result in better
lung deposition than the CFC formulation; approxi-
mately 60%of the BDPdose is depositedin the lungusing
a HFA propellant (173). The use of HFA-propelled BDP
has also been reported to result in a reduction in the
number of asthma exacerbations, even at a lower dose
of inhaled corticosteroid, than CFC-propelled BDP
(16?9% vs. 22?7% respectively) (174), and 40% fewer dis-
continuations from exacerbations than CFC-propelled
BDP (175).These ¢ndings are consistentwith thehypoth-
esis that treatment of the small airways may decrease
asthma exacerbation rates. HRCT scanning has shown
that HFA-corticosteroid aerosols have greater e⁄cacy
than the same dose of the larger particle size CFC-corti-
costeroid aerosol on small airways function, most likely
due to themore e¡ective delivery to the lung periphery
(80).The downside to enhanced delivery to the small air-
waysmaybe an increased incidence of side-e¡ects due to
the increased concentration of the drug being absorbed
from the lung and increased systemic bioavailability of
drug. While dose-related e¡ects of corticosteroids onthe surrogate markers of in£ammation have been de-
monstrated in patients with mild to moderate asthma,
higher doses (800^1600mgday71) are associated with
adrenal suppression and a decrease in the therapeutic in-
dex (176). It has been recommended that with doses in
excess of 800mgday71, a large-volume spacer device is
used to lessen local adverse e¡ects and reduce systemic
absorption (177).
While HFA-propelled BDP may provide greater de-
position, the involvement of the small airways means
that small luminal calibres or closed airwaysmay be pre-
sent. This will have the e¡ect of decreasing peripheral
deposition even when modern devices and improved in-
halation techniques are used.
THERENAISSANCEOFORAL/
SYSTEMICTHERAPY?
Traditional systemic drugs, such as the oral corticoster-
oids, are potent but non-speci¢c anti-in£ammatory
drugs, as indicatedby their action at a number of physio-
logical sites.Thus, to avoidunacceptable systemic side-ef-
fects, corticosteroids should be given locally via
inhalation. The drawback of inhaled therapy is that it
does not reach all the anatomical regions of the lung.
Since metered-dose inhalers deliver most of the dose to
the central airways (178), it is likely the peripheral air-
ways will not be a¡ected. Delivery of an anti-in£amma-
tory drug to the small airways via the pulmonary blood
supply may be a better approach in the treatment of
asthma since this will target not only the epithelial cells
of the airway, but also the smooth muscle and other ad-
ventitial cells.This is especially important in the periph-
eral airways where the focus of in£ammation appears to
be localized deeper in the tissue compared with the lar-
ger airways (93). In addition, the use of inhaled therapies
means that the systemic aspect of asthma, which a¡ects
areas other than the lung, are not treated.
Compliance with long-term regimens is a known pro-
blem, particularly when the symptoms are controlled.
With asthma therapy, non-compliance is generally esti-
mated to be around10^46% (179).However, studies have
shown that better compliance is achieved with oral than
with inhaled therapy (180), as many patients prefer
tablets to inhalers (179) and a simpli¢ed treatment regi-
men. Oral medication may also control concomitant
allergic conditions such as rhinitis and atopic dermatitis.
Leukotriene receptor antagonists represent a new
class of systemically or orally administered drugs that
have a more disease-speci¢c mode of action.The cystei-
nyl leukotrienes (Cys-LTs) are lipid mediators generated
from the metabolism of arachidonic acid and play an im-
portant role in the pathogenesis of asthma (181,182).This
role lies in the process of asthmatic in£ammation that
results in bronchoconstriction, bronchial hyper-respon-
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(181).Theymay also induce aspects of the chronic remo-
delling response seen in asthma.They are only produced
during the diseaseprocess and so blockade of theCys-LT
receptor is not associated with disturbance of normal
physiological function. Only the e¡ects of leukotrienes
are blocked and thus disease-speci¢c mediators are
being targeted.Therefore, the leukotriene receptor an-
tagonists may be given systemically without interfering
with normal physiological function.
Given systemically the leukotriene receptor antago-
nists reach the large and small airways, as well as having
an e¡ect on the other systemic disease-speci¢c involved
in asthma, including the nose and bone marrow (183).
Expression of leukotriene receptors has been shown on
a number of di¡erent cells, not only in lung tissue, but
also in progenitor stem cells in bonemarrow (184).They
have also been shown to have bene¢cial e¡ects on the
established clinical correlates of small airway function in
both adults and children (185^187).
Other examples of new therapeutic principles for
asthma are theuse of anti-IgE antibodies.There is a clear
associationbetweenelevatedlevels of IgE andclinical dis-
ease. It has been demonstrated that systemically admi-
nistered anti-IgE reduces levels of IgE and results in
clinical improvements of asthma. A recombinant huma-
nised monoclonal antibody that forms complexes with
free IgE has been shown to block the interaction of IgE
withmast cells and basophils (188). In early clinical inves-
tigations, this antibody attenuated the early-phase and
late-phase airway-obstructive response to challenge by
allergen and suppressed the accumulation of eosinophils
in the airway (189,190). Subsequent evaluation showed
that regular intravenous administration of this prepara-
tion to patients withmoderate or severe allergic asthma
controlled symptoms better than placebo and allowed a
clinically signi¢cant reduction in the dose of oral and in-
haled corticosteroids (188). Also, therapy waswell toler-
ated with few side-e¡ects despite the drug being given
systemically (188).
Speci¢c cytokine antagonists, inhibitors of T cell func-
tion, selective inducible nitric oxide synthase inhibitors,
and even gene-directed strategies such as DNAvaccines
are other examples of an evolving area of novel thera-
peutic approaches to treat the in£ammation in asthma
(191,192).
The future direction in treating asthma is likely to
be a systemically administered medication that has
few side-e¡ects and is targeted speci¢cally to the patho-
genesis of asthma (117). In addition to reaching the small
airways of the lung an ideal drug therapy for asthma
should target disease-speci¢c mediators. The leuko-
triene receptor antagonists are representatives of this
new class of drugs and we look forward to an exciting
future for the treatment of asthma as other drugs
emerge.CONCLUSIONS
Although it has been known formany years that asthma
is an in£ammatory disorder, there is now accumulating
evidence that in£ammation and other pathophysiological
changes in the small airways are important in all stages of
asthma (18,52,87,88,93). Therefore, to achieve suppres-
sion of in£ammation throughout the lung, treatment
should be directed at both the large and small airways.
Control of in£ammation in the small airways is particu-
larly critical in early stages of asthma (110).
The di⁄culty in measuring changes in the small air-
ways due to the lack of speci¢city, sensitivity and consis-
tency of pulmonary function tests has resulted in the
considerable under-estimation of the role of these
airways in asthma.Newer HRCT techniques have led to
advances in our ability to assess abnormalities in the
small airways, but despite this there is still no single
method that su⁄ciently measures small airways func-
tion.Clinicians therefore need to consider a combination
of objectivemeasures and clinical correlateswhen evalu-
ating their patients’condition.
Current understanding de¢nes asthma as an in£am-
matory disease.However, recent evidence suggests that
the in£ammatory process extends to the most distal
parts of the lung andevenbeyond, involving the systemic
components such as the nose and bone marrow
(24,25,29,30,33). The view that asthma is a systemic dis-
order supports the use of systemic therapies for asthma
(46).
While the initial approach to treating asthmawas sys-
temic, the early oral therapies were associatedwith ser-
ious side-e¡ect pro¢les.Consequently, inhaled therapies
were developed in an attempt to decrease the systemic
side-e¡ects.However, inhaled therapies, such as the cor-
ticosteroids, have a non-speci¢c anti-in£ammatory ef-
fect and may a¡ect a number of organs apart from the
lung. Such e¡ects result from the gastrointestinal and
pulmonary absorption of the inhaled drug (140,147).
Although inhaled therapies decrease in£ammation in
the large airways theymay not be as e⁄cient in treating
small airways in£ammation (18,160,165). The majority of
the inhaled dose is deposited in the central airways and
only a small proportion reaches the peripheral airways
(52,87,172). In addition, inhaled therapies do not treat
the systemic aspect of asthma.
Since asthma is nowunderstood to beboth a systemic
and small airways disease, a treatment is neededwhich is
systemically or orally administered, is able to reach the
small airways and targets disease-speci¢c mediators,
both in the lung and systemically, without a¡ecting nor-
mal physiological functions.
The leukotriene receptor antagonists are representa-
tives of a newclass of drugs for treatmentof asthma that
o¡er this new approach. Anti-IgE and cytokine antago-
nists are further examples, and the arrival of other new
HISTORYANDFUTUREPERSPECTIVESOFASTHMATREATMENT 715therapeutic strategies is awaited.The future for asthma
therapy is likely to focus on targeting a combination of
disease-speci¢c mediators to achieve optimal disease
outcomes in asthma.
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